Clinical Studies – Targeting Acute and Chronic Thromboembolic Disorders
First Published, Prospective, International, Observational Study of a NOAC for the Treatment and Secondary Prevention of VTE
XALIA:
First Published, Prospective, International, Observational Study with a NOAC (Xarelto®) in DVT1
Objective
-
Collect Real-World data in patients with acute DVT treated with Xarelto or standard anticoagulation therapy*,1
Study design
Population
5,142 adults with acute DVT and an indication to receive anticoagulation therapy for at least 3 months, who were treated with Xarelto or standard anticoagulation therapy*,1
Key patient characteristics of Xarelto patients are consistent with EINSTEIN DVT 2
CrCl, creatinine clearance; DVT , deep vein thrombosis ; VTE , venous thromboembolism. * Initial treatment with unfractionated heparin, low-molecular-weight heparin or fondaparinux; usually overlapping with and followed by a vitamin K antagonist.
PP-XAR-ALL-1819-1
References
- Ageno W, et al. Lancet Haematol. 2016;3(1):e12–e21. Ageno W, et al. Lancet Haematol. 2016;3(1):e12–e21. Return to content
- Bauersachs R, et al. N Engl J Med. 2010;363:2499–2510. Bauersachs R, et al. N Engl J Med. 2010;363:2499–2510. Return to content
